Assessment Of Short Preoperative Endocrine Therapy In The Adapt And Adaptcycle Trials

Assessment of short preoperative endocrine therapy in the ADAPT and ADAPTcycle trials

Impact of age, RS and OFS on endocrine response to short preoperative ET

Impact of age and ovarian function suppression on endocrine response to short preoperative endoc...

ADAPT trial: Endocrine + ribociclib vs. chemotherapy in HR+/HER2- early breast cancer

ADAPTCycle: Adjuvant personalised therapy comparing endocrine therapy plus ribociclib versus che...

Dr. Yee on Phase II ADAPT Trial Results for HER2+/HR+ Breast Cancer

New horizons in high-risk HR+ HER2- EBC: Risk stratification for early identification

Touch Medical Media

Evaluating the Role of Neoadjuvant Endocrine Therapy in Breast Cancer

Targeted Oncology

A correlative analysis of CORALLEEN: preoperative ribociclib +letrozole vs chemo in HR+/HER2- BC

Outcomes from ADAPT-HR-/HER2+ evaluating dual HER2 blockade

The latest in neo-adjuvant therapy for luminal breast cancer

monarchE: adjuvant abemaciclib + endocrine therapy in patients with HR+, HER2- high-risk eBC

Phase II ADAPT Trial in Patients With HER2+ and HR+ Early Breast Cancer

Targeted Oncology

How do the ADAPT trial results compare with the RxPonder results?

Breast cancer trials of interest at ESMO 2022

Raising the Bar in HR+/HER2- Early Breast Cancer: CDK4 and 6 Inhibitors

PeerView Oncology

Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HE...

WSG TP-II trial: survival outcomes of de-escalated treatments in HER2+ breast cancer

Analysis of BRCA1/2 mutations and other alterations in the monarchE trial

Session 9: Adjuvant endocrine therapy for premenopausal women: Risk stratification, type & duration